TransMedics (TMDX) Short term Debt (2025 - 2026)

TransMedics (TMDX) recorded quarterly Short term Debt of $15.0 million in Q1 2026, up 50.0% quarter-over-quarter from $10.0 million in Q4 2025.

TransMedics (TMDX) Short term Debt (2025 - 2026) Analysis & Trends

TransMedics' Short term Debt history runs 2 years deep, the most recent figure standing at $15.0 million for Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (changed N/A YoY), while the FY2025 annual figure was $10.0 million, changed N/A from the prior year.
Short term Debt was $15.0 million for Q1 2026 at TransMedics, up from $10.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $15.0 million in Q1 2026 to a low of $5.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	TransMedics	2.72 Bn	2.26 Bn	101.16 Mn

Download Data